Plasma Brain-Derived Neurotrophic Factor Levels Predict the Clinical Outcome of Depression Treatment in a Naturalistic Study
Figure 2
Changes in plasma BDNF levels in MDD patients (remission [▪, n = 38] and non-responder [□, n = 10] groups).
The period-matched symptom-response and symptom-remission outcomes were examined at 8 and 12 weeks, respectively, in the non-responder group. Plasma BDNF levels were measured by immunoassay. Each point represents the mean. The statistical significance of differences was calculated using repeated-measures ANOVA with post-hoc Bonferroni testing (*p<0.05). The statistical significance of differences in plasma BDNF levels between remission (▪) and non-responder (□) groups at the depressive syndrome stage were calculated using the Students’ t-test (#p<0.05).
